Comparable Efficacy, Improved Safety and Lower Cost for High-Dose Bolus Dosing of AGGRASTAT Compared to ReoPro in STEMI Patients Undergoing Primary PCI: Three-Year Follow-Up for MULTISTRATEGY

GENEVA--(BUSINESS WIRE)--Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT® (tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro® (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.